杨雅舒医师:该研究的伦理审批文件未上传,请尽快上传。 两种不同消融策略治疗持续性心房颤动的对比研究

注册号:

Registration number:

ChiCTR1900028439 

最近更新日期:

Date of Last Refreshed on:

2019-12-21 22:25:29 

注册时间:

Date of Registration:

2019-12-21 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

杨雅舒医师:该研究的伦理审批文件未上传,请尽快上传。 两种不同消融策略治疗持续性心房颤动的对比研究

Public title:

Comparative Study of Two Different Ablation Strategies for the Treatment of Persistent Atrial Fibrillation

注册题目简写:

English Acronym:

研究课题的正式科学名称:

两种不同消融策略治疗持续性心房颤动的对比研究

Scientific title:

Comparative Study of Two Different Ablation Strategies for the Treatment of Persistent Atrial Fibrillation

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

杨雅舒 

研究负责人:

杨平珍 

Applicant:

Yashu Yang 

Study leader:

Pingzhen Yang 

申请注册联系人电话:

Applicant telephone:

+86 13265050215

研究负责人电话:

Study leader's
telephone:

+86 13902402246

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

yashuyang@126.com

研究负责人电子邮件:

Study leader's E-mail:

y.pingzhen@yahoo.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

广东省广州市海珠区工业大道中253号

研究负责人通讯地址:

广东省广州市海珠区工业大道中253号

Applicant address:

253 Industrial Avenue Middle, Haizhu District, Guangzhou, Guangdong

Study leader's address:

253 Industrial Avenue Middle, Haizhu District, Guangzhou, Guangdong

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

南方医科大学珠江医院

Applicant's institution:

Zhujiang Hospital of Southern University

研究负责人所在单位:

南方医科大学珠江医院

Affiliation of the Leader:

Zhujiang Hospital of Southern University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2019-KY-039-01

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

南方医科大学珠江医院医学理论委员会

Name of the ethic committee:

Medical Theory Committee of Zhujiang Hospital of Southern Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2019-06-19 00:00:00

伦理委员会联系人:

张婷婷

Contact Name of the ethic committee:

Tingting Zhang

伦理委员会联系地址:

广东省广州市海珠区工业大道中253号

Contact Address of the ethic committee:

253 Industrial Avenue Middle, Haizhu District, Guangzhou, Guangdong

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

南方医科大学珠江医院

Primary sponsor:

Zhujiang Hospital of Southern University

研究实施负责(组长)单位地址:

广东省广州市海珠区工业大道中253号

Primary sponsor's address:

253 Industrial Avenue Middle, Haizhu District, Guangzhou, Guangdong

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东

市(区县):

广州

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

南方医科大学珠江医院

具体地址:

海珠区工业大道中253号

Institution
hospital:

Zhujiang Hospital of Southern Medical University

Address:

253 Industrial Avenue Middle, Haizhu District

经费或物资来源:

自筹

Source(s) of funding:

Self-raised

研究疾病:

持续性心房颤动  

Target disease:

persistent atrial fibrillation

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

本研究拟通过两种不同消融术式治疗持续性房颤的对比研究,探讨二尖瓣峡部线消融对于持续性心房颤动射频导管消融治疗效果以及射频消融治疗持续性 房颤的安全性和有效性。  

Objectives of Study:

This study is to investigate the efficacy of mitral isthmus ablation for radiofrequency catheter ablation of persistent atrial fibrillation and evaluate the safety and effectiveness of radiofrequency ablation for persistent atrial fibrillation by a comparative study of two different ablation strategies for persistent atrial fibrillation.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1. 左房直径(前后径)>50mm;
2. 既往有房颤、房扑或房速消融手术史或先心病外科手术史;
3. 瓣膜性房颤;
4. LVEF<30%;5.抗凝禁忌或左心耳血栓。

Exclusion criteria:

1. Left atrial diameter (anteroposterior diameter)> 50mm;
2. Previous history of atrial fibrillation, atrial flutter or atrial ablation surgery or congenital heart surgery;
3. Valvular atrial fibrillation;
4. LVEF <30%;
5. Anticoagulation contraindications or left atrial appendage thrombosis.

研究实施时间:

Study execute time:

From 2019-12-23 00:00:00 To 2024-12-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2019-12-23 00:00:00 To 2021-12-01 00:00:00

干预措施:

Interventions:

组别:

A组

样本量:

64

Group:

Group A

Sample size:

干预措施:

双侧环肺静脉隔离联合左房顶部线消融

干预措施代码:

Intervention:

circumferential pulmonary vein ablation combined with left atrial top line linear ablation

Intervention code:

组别:

B组

样本量:

64

Group:

Group B

Sample size:

干预措施:

双侧环肺静脉消融、左房顶部线线性消融联合二尖瓣峡部线线性消融

干预措施代码:

Intervention:

circumferential pulmonary vein ablation, left atrial top line linear ablation combined with mitral isthmus linearity ablation

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广东 

市(区县):

广州 

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

南方医科大学珠江医院 

单位级别:

三级甲等医院 

Institution
hospital:

Zhujiang Hospital of Southern University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

窦性心律维持率

指标类型:

主要指标

Outcome:

the restoration rate of sinus rhythm

Type:

Primary indicator

测量时间点:

测量方法:

心电图

Measure time point of outcome:

Measure method:

ECG

指标中文名:

窦性心律维持时间

指标类型:

主要指标

Outcome:

sinus rhythm maintaining time

Type:

Primary indicator

测量时间点:

测量方法:

动态心电图

Measure time point of outcome:

Measure method:

Dynamic ECG

指标中文名:

心脏结构

指标类型:

次要指标

Outcome:

Cardiac structure

Type:

Secondary indicator

测量时间点:

测量方法:

心脏彩超

Measure time point of outcome:

Measure method:

echocardiography

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

N/A

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

随机数表

Randomization Procedure (please state who generates the random number sequence and by what method):

Random number table

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

对参试者设盲

Blinding:

Blind method for subjects.

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

Not stated

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Not stated

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

Not stated

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Not stated

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2019-12-21 22:25:29